Research and Development Expenses Breakdown: Pfizer Inc. vs Alnylam Pharmaceuticals, Inc.

R&D Spending: Pfizer vs. Alnylam - A Decade of Innovation

__timestampAlnylam Pharmaceuticals, Inc.Pfizer Inc.
Wednesday, January 1, 20141902490008393000000
Thursday, January 1, 20152764950007690000000
Friday, January 1, 20163823920007872000000
Sunday, January 1, 20173906350007657000000
Monday, January 1, 20185054200008006000000
Tuesday, January 1, 20196551140008650000000
Wednesday, January 1, 20206548190009405000000
Friday, January 1, 202179215600013829000000
Saturday, January 1, 202288301500011428000000
Sunday, January 1, 2023100441500010679000000
Monday, January 1, 2024112623200010930000000
Loading chart...

Unveiling the hidden dimensions of data

A Decade of Innovation: R&D Spending in Pharmaceuticals

In the ever-evolving world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Pfizer Inc. and Alnylam Pharmaceuticals, Inc. have demonstrated contrasting yet fascinating trajectories in their R&D investments.

From 2014 to 2023, Pfizer consistently allocated substantial resources to R&D, with expenditures peaking at approximately $13.8 billion in 2021. This represents a 65% increase from their 2014 spending, underscoring Pfizer's commitment to maintaining its leadership in the industry.

Conversely, Alnylam Pharmaceuticals, a smaller yet dynamic player, showcased a remarkable growth trajectory. Their R&D expenses surged by over 400% during the same period, reaching around $1 billion in 2023. This growth highlights Alnylam's aggressive pursuit of innovation, particularly in the field of RNA interference therapeutics.

These trends reflect the broader industry dynamics, where established giants and nimble innovators alike are investing heavily in the future of medicine.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025